Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.43 |
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070043 | 0.92 | AR (0.44) | ARMAP3K14SLC22A12PTGDR2GAA | |
| SCHEMBL3083992 | 0.92 | AR (0.46) | ARMAP3K14ADRA1DPTGDR2 | |
| SCHEMBL3080777 | 0.91 | CASP1 (0.47) | ARMAP3K14ADRA1DCASP1 | |
| SCHEMBL3083455 | 0.90 | AR (0.48) | ARMAP3K14GAAHTTNPSR1 | |
| SCHEMBL3074286 | 0.90 | AR (0.43) | ARMAP3K14PTGDR2GAAHTT | |
| SCHEMBL3069070 | 0.89 | AR (0.46) | ARSLC22A12PTGDR2 | |
| SCHEMBL3077659 | 0.88 | AR (0.44) | ARMAP3K14SLC22A12ADRA1DPTGDR2 | |
| SCHEMBL3088707 | 0.86 | AR (0.44) | ARMAP3K14SLC22A12ADRA1DPTGDR2 | |
| SCHEMBL3087505 | 0.86 | AR (0.43) | ARMAP3K14PTGDR2GAANPSR1 | |
| SCHEMBL3077678 | 0.86 | AR (0.46) | ARSLC22A12ADRA1DPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101842357-A | Substituted pyrazole derivatives | TAKEDA PHARMACEUTICAL | 2010-09-22 | — | — | CN | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | AR 1/4885MAP3K14 2023/4885SLC22A12 1644/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | AR 1/4885MAP3K14 2053/4885SLC22A12 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.